Zobrazeno 1 - 10 of 29 pro vyhledávání: '"M, Jurado Chacón"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
4CPS-103 Evaluation of health outcomes of daratumumab in monotherapy in adult patients with relapsed refractory multiple myeloma
Autor: JE Martínez-de la Plata, R Ríos Tamayo, M. E. Clavero Sánchez, C Alarcon-Payer, A Jiménez Morales, M. Jurado Chacón, S Cano Domínguez
Publikováno v: Section 4: Clinical Pharmacy Services.
Background Immunotherapy has broken new ground in the treatment of multiple myeloma, with the introduction of monoclonal antibodies into the therapeutic arsenal, representing a paradigm shift in treatment. Daratumumab is a human monoclonal antibody I
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::39dd75a3c3049c395bb13af1d84d2564
https://doi.org/10.1136/ejhpharm-2019-eahpconf.252
Zobrazit plný text záznamu
3
4CPS-194 Clinical impact of genomic biomarkers predictors of response and the therapeutic strategy in patients with myelodysplastic syndrome associated with del(5q)
Autor: C Alarcón Payer, M. Jurado Chacón, A Jiménez Morales, F. Hernández Mohedo, C. García Collado
Publikováno v: Section 4: Clinical Pharmacy Services.
Background According to OMS-2016, myelodysplastic syndrome (MDS) associated with del(5q) is manifested by a transfusion-dependent progressive bone marrow failure, with Lenalidomide acting as the intended drug to treat this syndrome. Purpose To analys
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::26a7a0e8851d44fdba7b3a903c2d2674
https://doi.org/10.1136/ejhpharm-2019-eahpconf.343
Zobrazit plný text záznamu
4
4CPS-102 Measurement of health outcomes of pomalidomide, cyclophosphamide and dexamethasone combination in adult patients with relapsed and refractory multiple myeloma
Autor: R Ríos Tamayo, M Jurado Chacón, A Jiménez Morales, C Alarcon-Payer, S Cano Domínguez
Publikováno v: Section 4: Clinical Pharmacy Services.
Background Multiple myeloma is a plasma cell malignancy that accounts for 1% of all cancers. Despite available therapies, the disease remains uniformly fatal, and patients who have received prior lenalidomide and bortezomib have a median overall surv
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f500e2d925ade9cf09bc248842d78c33
https://doi.org/10.1136/ejhpharm-2019-eahpconf.251
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje